🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Rocatinlimab, Placebo for AMG 451

    Amgen

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  2. Ropivacaína Altan 2 mg/ml solución inyectable EFG, Adrenalina B. Braun 1 mg/ml Solución Inyectable

    The George Institute

    lumbar arthrodesis

    phase 3 small molecule active

    1 trial

  3. Rozanolixizumab, also known as UCB7665, Rystiggo 140 mg/ml solution for injection, -

    Lacuna Pharma Pty Ltd

    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)

    phase 3 small molecule active

    1 trial

  4. Rozlytrek, Rozlytrek, RO 743-5846/F06, Ipatasertib, Rozlytrek, INAVOLISIB, Ipatasertib, INAVOLISIB, RO7538483, Rozlytrek 200 mg hard capsules, Rozlytrek 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, RO 743-5846/F04, Tecentriq 1 200 mg concentrate for solution for infusion, ABIRATERONE

    Hoffmann-La Roche

    This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally

    phase 3 small molecule active

    1 trial

  5. Rukobia 600 mg prolonged-release tablets

    ViiV Healthcare Pty Ltd

    Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant (MDR) HIV-1

    phase 3 small molecule active

    1 trial

  6. Rybelsus 3 mg tablets, Rybelsus 14 mg tablets, Placebo (semaglutide) tablets, Rybelsus 7 mg tablets

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  7. Rybelsus 7 mg tablets, Placebo (semaglutide) tablet, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  8. Rybelsus 7 mg tablets, Placebo (semaglutide) tablets, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  9. Ryzodeg 100 units/mL FlexTouch solution for injection in pre-filled pen, IcoSema 700 U/mL + 2 mg/mL PDS290

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  10. SALBUTAMOL , Tozorakimab, Tozorakimab-placebo

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  11. SALINE, GEMCITABINE, GEMCITABINE, Quemliclustat, GEMCITABINE, PACLITAXEL ALBUMIN-BOUND

    Arcus Biosciences

    Pancreatic cancer, Metastatic Pancreatic ductal adenocarcinoma (mPDAC), Pancreatic ductal adenocarcinoma (PDAC)

    phase 3 small molecule active

    1 trial

  12. SARCLISA 20mg/mL concentrate for solution for infusion., Iclusig 15 mg film-coated tablets, SARCLISA 20mg/mL concentrate for solution for infusion., BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion.

    Pari Pharma GmbH

    Patients aged 18-65 years old with newly diagnosed previously untreated ALL or T-LL.

    phase 3 small molecule active

    1 trial

  13. SB11 (Proposed ranibizumab biosimilar)

    Samsung Bioepis NL B.V.

    Age-Related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  14. SECUKINUMAB

    Novartis Pharmaceuticals

    Polymyalgia Rheumatica

    phase 3 small molecule active

    1 trial

  15. SELINEXOR, Selinexor placebo for 20 mg tablets is formulated for oral administration. selinexor placebo tablets are film coated bi-convex round tablets

    Karyopharm Therapeutics Inc

    endometrial cancer

    phase 3 small molecule active

    1 trial

  16. SELPERCATINIB, CARBOPLATIN , SELPERCATINIB, PEMBROLIZUMAB, CISPLATIN , PEMETREXED

    Eli Lilly Co.

    Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  17. SELUMETINIB, SELUMETINIB, Placebo to match Selumetinib capsules, 10 and 25 mg.

    AstraZeneca AB

    Neurofibromatosis Type 1 (NF1) with Symptomatic, Inoperable Plexiform Neurofibromas (PN).

    phase 3 small molecule active

    1 trial

  18. SHR-1210

    Jian Li

    Locally Advanced or Metastatic and Unresectable HCC

    phase 3 small molecule completed

    1 trial

  19. SODIO CLORURO 0,9% BAXTER Soluzione per infusione, KETAMINA MOLTENI 50 mg/ml soluzione iniettabile

    Talion

    Major Depressive Disorder (MDD)

    phase 3 small molecule active

    1 trial

  20. SODIO CLORURO 0,9% BAXTER Soluzione per infusione, KETAMINA MOLTENI 50 mg/ml soluzione iniettabile

    Talion

    Major Depressive Disorder (MDD)

    phase 3 small molecule active

    1 trial

  21. SODIUM CHLORIDE , RITUXIMAB, MYCOPHENOLIC ACID

    Tour Hekla

    Intersitial lung disease related to systemic sclerosis

    phase 3 small molecule active

    1 trial

  22. SODIUM CHLORIDE, HYDROCORTISONE UPJOHN 100 mg, préparation injectable, Placebo of hydrocortisone 100 mg, Reverpleg 40 U.I./2 ml solution à diluer pour perfusion

    Pari Pharma GmbH

    Adult cardiac arrest patients with sustained ROSC and hemodynamic failure due to post-resuscitation syndrome

    phase 3 small molecule active

    1 trial

  23. SODIUM CHLORIDE, MYCOPHENOLATE MOFETIL, GLUCOSE, Oleclumab, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion., Monalizumab, IMFINZI 50 mg/mL concentrate for solution for infusion., INFLIXIMAB

    AstraZeneca AB

    Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  24. SODIUM CHLORIDE, Truxima 500 mg concentrate for solution for infusion

    Pari Pharma GmbH

    Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%) following RTX induction treatment

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources